Srinagar Magazine

With 33.9% CAGR, Global (AI) Artificial Intelligence in Drug Discovery Market Share Estimated to Reach USD 5,558.0 Million by 2029: Polaris Market Research

 Breaking News
  • No posts were found

With 33.9% CAGR, Global (AI) Artificial Intelligence in Drug Discovery Market Share Estimated to Reach USD 5,558.0 Million by 2029: Polaris Market Research

April 12
20:43 2022
With 33.9% CAGR, Global (AI) Artificial Intelligence in Drug Discovery Market Share Estimated to Reach USD 5,558.0 Million by 2029: Polaris Market Research
According to the research report, the global (AI) artificial intelligence in drug discovery market size & share was valued at USD 626.6 Million in 2021 and is expected to reach USD 5,558.0 Million by 2029, to grow at a CAGR of 33.9% during the forecast period.

According to the research report, the global (AI) artificial intelligence in drug discovery market size & share was valued at USD 626.6 Million in 2021 and is expected to reach USD 5,558.0 Million by 2029growing at a CAGR of 33.9% during the forecast period.

Spearheading biopharmaceutical companies’ trust in AI is because of increasing consciousness connected to AI in the pharmaceutical sector and funding in drug development. AI functions with the brand-new modern processes of biology and chemistry to advance the most recent algorithms. It can gesture drug screening from the bench to the lab that is virtual without the requirement of a substantial speculative workforce and input. Most substantial biopharmaceutical companies have begun programs that are internal or are cooperating to advance AI platforms for growing the research power of metabolic disease therapy, immune-oncology drugs, and cancer treatments.

AI can furnish value in small molecule drug discovery in four ways: new biology access, enhancement or new chemistry, superior rates of success, and speedy and cost-effective discovery procedures. The technology can orate many confrontations and restrictions in conventional R&D. Each application paves the way for supplementary perception to drug discovery teams and often can radically reconsider long-standing workflows.

Request Sample Copy of Research Report @ https://www.polarismarketresearch.com/industry-analysis/ai-in-drug-discovery-market/request-for-sample

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)

Important Questions Being Answered by The Market Report

  • What is the market size and growth?
  • What is the market value of AI in drug discovery market?
  • The base year computed in AI in drug discovery market report?
  • Which are the top companies that hold the market share?
  • Which is the most influencing segment evolving?
  • What are the key trends?

 

Top Market Players Are:

  • Atomwise
  • Benevolent AI
  • Berg Health
  • BIOAGE
  • BioSymetrics
  • Cloud Pharmaceuticals
  • Cyclica
  • Deep Genomics
  • DeepMind
  • Envisagenics
  • Euretos
  • Exscientia
  • GNS Healthcare
  • IBM Corporation
  • Insilico Medicine
  • Insitro
  • NuMedii
  • Numerate
  • NVIDIA Corporation
  • OWKIN Inc.
  • Aria Pharmaceuticals Inc.
  • Verge Genomics
  • XtalPi Inc.

 

Request for Discount on this Report Before Purchase @ https://www.polarismarketresearch.com/industry-analysis/ai-in-drug-discovery-market/request-for-discount-pricing

AI in drug discovery market: Growth leading factors

AI has been broadly used in the healthcare sector, particularly in searching for new drugs. This quality can recognize drug targets and play an essential part in identifying, developing, detecting, and screening minute molecules in less time. Additionally, the market is anticipated to observe an aggressive growth in the forecast period because of the advantages of using these progressive techniques over traditional procedures.

At a rapid pace, the incidence of chronic disease is increasing globally. Chronic illnesses like diabetes and heart disease are the prime causes of death. These factors highlight the increasing prevalence of chronic diseases and a requirement to depose the fatality rate due to these illnesses. AI platforms utilized for drug discovery can be an alternative for attaining insights into drug discovery to minimize the severity of many chronic diseases.

The covid-19 pandemic has impacted several industries globally. Governments across the world applied stringent lockdown measures. Social distancing norms were also implemented to curb the looming pandemic. Manufacturing facilities globally were clamped down. Additionally, the economic crisis after the pandemic led to a notable delay in the commercial inauguration of the healthcare industry.

Directly Purchase a copy of the report with TOC @ https://www.polarismarketresearch.com/checkouts/8171

AI in drug discovery market: Report Scope

Report Attribute

Details

Market Size 2021 Value

USD 626.6 million

Market Outlook for 2029

USD 5,558.0 million

Expected CAGR Growth

33.9% from 2022 – 2029

Base year

2021

Forecast period

2022 – 2029

Segments covered

By Application, By Therapeutic Area, By Offering, By Technology, By Region

Key Companies

Atomwise, Benevolent AI, Berg Health, BIOAGE, BioSymetrics, Cloud Pharmaceuticals, Cyclica, Deep Genomics, DeepMind, Envisagenics, Euretos, Exscientia, GNS Healthcare, IBM Corporation, Insilico Medicine, Insitro, NuMedii, Numerate, NVIDIA Corporation, OWKIN, Inc., Aria Pharmaceuticals, Inc., Verge Genomics, XtalPi Inc.

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Customization Options

Customized purchase options are available to meet your research needs.

 

AI in drug discovery market: Key segmentation

  • Insight by application, therapeutic area, offering, technology, and region

 

Based on the therapeutic area, neurodegenerative diseases form the speedily growing segment because of the capacity of AI to discover drugs for complicated conditions and the priority of market players to offer AI-dependent platforms for neurological diseases. By application, the optimizing and repurposing segment is deemed the most significant revenue share in the industry. It is cost-effective and only requires electronic medical records (EMR) for medicine repurposing. By offering, the software segment held the largest market share because of factors like less cost and time to market the drug, lesser failure rate, and a vast number of software developers for drug discovery.

Regional Analysis

By region, North America emerged as the biggest and the speedily growing regional market for AI in drug discovery. North America consists of Canada, the US, and Mexico, forming the biggest market for AI in drug discovery. These countries have been associated with AI technology in drug discovery and development for several years. The US is a significant contributor to the North American market. Also, important AI technology sources like Google, IBM, NVIDIA, Microsoft, and Intel are situated in the US, where their robust presence was a key benefactor to the growth of the market.

Browse the full “Artificial Intelligence in Drug Discovery Market Share, Size, Trends, Industry Analysis Report, By Application (Drug Optimization & Repurposing, Preclinical testing, Others); By Therapeutic Area; By Offering; By Technology; By Region; Segment Forecast, 2022 – 2029” Report at https://www.polarismarketresearch.com/industry-analysis/ai-in-drug-discovery-market

Key highlights of the report

  • Qualitative and quantitative investigation of the market dependent on segmentation, including both economic and non-economic factors
  • Supplying market value data for each segment and sub-segment
  • Points toward the region and segment that is anticipated to observe speedy growth as well as dominate the market
  • Inspection by geography underscores the intake of services and products in the area and highlights the factors that are influencing the market within each region
  • Competitive landscape which includes the market classification of prominent players together with new products and service launches, business expansions, partnerships, and accession in the past five years of the company being profiled
  • Substantial company profiles including an overview of the company, insights of the company, benchmarking of the product, and SWOT analysis for the prominent market players

 

The market primarily depends on the application, therapeutic area, offering, technology, and region

AI in drug discovery market: By application

  • Drug Optimization & Repurposing
  • Preclinical Testing
  • Others

 

AI in drug discovery market: By therapeutic area

  • Oncology
  • Neurodegenerative Diseases
  • Cardiovascular Disease
  • Metabolic Diseases
  • Infectious Disease
  • Others

AI in the drug discovery market: By offering

  • Software
  • Services

 

AI in drug discovery market: By technology

  • Machine Learning
    • Deep Learning
    • Supervised Learning
    • Reinforcement Learning
    • Unsupervised Learning
    • Other Machine Learning Technologies
  • Other Technologies

 

About Us:

Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semiconductors, chemicals, automotive, and aerospace & defense, among different ventures, present globally.

Media Contact
Company Name: Polaris Market Research and Consulting
Contact Person: Likhil
Email: Send Email
Phone: +1-9292-97-97-27
Address:30 Wall Street 8th Floor, New York City, NY 10005, United States
City: New York City
State: US
Country: United States
Website: https://www.polarismarketresearch.com/industry-analysis/ai-in-drug-discovery-market